[RI1001] RNAok™ RNase Inhibitor, 20 U/μl, 2000 U x 5
Facebook
X
Pinterest
Email
The RNAok™ RNase Inhibitor is a recombinant mammalian RNase inhibitor which possesses very high affinity for eukaryotic pancreatic-type ribonuclease. The RNAok™ RNase Inhibitor forms a 1:1 complex with pancreatic RNase A by noncovalent binding, presenting a noncompetitive inhibitory activity on these pancreatic enzymes. RNAok™ RNase Inhibitor is active against RNase A, RNase B, RNase C but not RNAse H, RNase I, RNase T1, RNase T2, and S1 nuclease. RNAok™ RNase Inhibitor is compatible with RT-PCR enzymes such as AMV, M-MLV and ExcelRT™ Reverse Transcriptase or Taq DNA polymerase.
Detail
Description
The RNAok™ RNase Inhibitor is a recombinant mammalian RNase inhibitor which possesses very high affinity for eukaryotic pancreatic-type ribonuclease. The RNAok™ RNase Inhibitor forms a 1:1 complex with pancreatic RNase A by noncovalent binding, presenting a noncompetitive inhibitory activity on these pancreatic enzymes. RNAok™ RNase Inhibitor is active against RNase A, RNase B, RNase C but not RNAse H, RNase I, RNase T1, RNase T2, and S1 nuclease. RNAok™ RNase Inhibitor is compatible with RT-PCR enzymes such as AMV, M-MLV and ExcelRT™ Reverse Transcriptase or Taq DNA polymerase.
Application
cDNA Synthesis
in vitro translation
in vitro transcription
One-step RT-PCR
Separation and identification of specific ribonuclease activities
Storage Buffer
40 mM HEPES-KOH (pH 7.5), 100 mM KCl, 8 mM DTT, 0.1 mM EDTA, stabilizer and 50% (v/v) glycerol
Cryptococcus neoformans is an encapsulated yeast. Infection with C. neoformans is known as cryptococcosis and is the cause of the most common life-threatening meningitis in patients with weakened immune systems, particularly in advanced HIV/AIDS. C. neoformans is commonly found in soil throughout the world. Human infection of C. neoformans occurs via inhalation of aerosolized spores. From the lungs, C. neoformans is spread hematogenously to the Central Nervous System (CNS), resulting in meningoencephalitis. Although the availability of antiretroviral therapy in the developed world has reduced the incidents of cryptococcosis, it is still a major problem in developing countries and is one of the leading causes of death in patients with HIV/AIDS. In fact, one of the major challenges in treating cryptococcosis is that many patients with cryptococcal CNS disease are asymptomatic in terms of cryptococcal pneumonia, making it difficult for early detection.
Storage Conditions and Product Stability All kit components can be stored for 2 years after the date of production without showing any reduction in performance.
All kit components should be stored at -20°C upon arrival. Repeated thawing and freezing (> 2 x) of the Master Mix and Positive Control should be avoided, as this may affect the performance of the assay. If the reagents are to be used only intermittently, they should be frozen in aliquots.
Key features： 1. High-definition LCD touch screen, simultaneously displaying operational parameters: speed, temperature, vacuum, and running time. 2. Delayed start: after reaching a fixed speed, Start the vacuum pump to effectively prevent sample mixing. 3. Fully automatic vacuum control system, vacuum setting range0.1~1000mbar, Control accuracy0.1mbar. 4. 1.5/2ml Rotor stacking for simultaneous use; rotor replacement without tools. 5. Programmable with temperature and pressure settings; capable of storing 36 programs 6. Compatible with various rotor heads; transparent glass window for easy observation. 7. Magnetic drive: maintenance-free, non-contact drive, fully sealed. 8. Safety in use: inductive electric self-suction door lock ensures the centrifugal concentrator can only start when the door cover is fully closed and locked. 9. Can be used in conjunction with freeze-drying systems Model: SD-25/SD-25C
